Report: Competitive Outlook on Apoptosis in Oncology TOC

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 Table of Contents

4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables

5 Introduction to Apoptosis in Oncology

6 Apoptosis Competitive Landscape in Oncology

6.1 Countries & Players: Who are In the Lead?
- 6.1.1 Top 10 Players Dominate The Developmental Pipeline
6.2 Deals & Alliances in Apoptosis Drug Development
- 6.2.1 Review of Deals and Alliances Initiated in 2006
- 6.2.2 Review of Deals and Alliances Initiated in 2005
- 6.2.3 Review of Deals and Alliances Initiated in 2004
- 6.2.4 Review of Deals and Alliances Initiated in 2003
- 6.2.5 Review of Deals and Alliances Initiated in 2002
- 6.2.6 Review of Deals and Alliances Initiated in 2001

7 Approved Apoptopic Cancer Drugs: Performance

8 Target Analysis in Apoptosis

8.1 Targets of Late Stage Apoptopic Drugs in Development
- 8.1.1 B-cell CLL/lymphoma 2
- 8.1.2 Caspase 3
- 8.1.3 CD4 molecule
- 8.1.4 Cytosolic ovarian carcinoma antigen 1
- 8.1.5 Eukaryotic translation elongation factor 2
- 8.1.6 Farnesyltransferase, CAAX box, alpha
- 8.1.7 Fc fragment of IgE
- 8.1.8 Histone deacetylase 1
- 8.1.9 Histone deacetylase 2
- 8.1.10 Interleukin 13 receptor, alpha 1
- 8.1.11 Phosphodiesterase 2A, cGMP-stimulated
- 8.1.12 Phosphodiesterase 5A, cGMP-specific
- 8.1.13 Protein kinase C, beta 1
- 8.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
- 8.1.15 Topoisomerase (DNA) I
- 8.1.16 Topoisomerase (DNA) II alpha
- 8.1.17 Tubulin, beta polypeptide
- 8.1.18 p53 protein
8.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
- 8.2.1 Targets in Breast Cancer
- 8.2.2 Targets in Leukemia
- 8.2.3 Targets in Lung Cancer
- 8.2.4 Targets in Lymphoma
- 8.2.5 Targets in Prostate Cancer

9 Apoptopic Drugs in Development: By Major Indications

9.1 General Drug Developmental Overview
- 9.1.1 Apoptopic Drugs in Phase III Clinical Development
- 9.1.2 Failed Apoptopic Drugs in Oncology
9.2 Progress Analysis - Breast Cancer
- 9.2.1 Phase I Clinical Development
- 9.2.2 Phase II Clinical Development
- 9.2.3 Phase III Clinical Development
9.3 Progress Analysis - Leukemia
- 9.3.1 Phase I Clinical Development
- 9.3.2 Phase II Clinical Development
- 9.3.3 Phase III Clinical Development
9.4 Progress Analysis - Lung Cancer
- 9.4.1 Phase I Clinical Development
- 9.4.2 Phase II Clinical Development
- 9.4.3 Phase III Clinical Development
9.5 Progress Analysis - Lymphoma
- 9.5.1 Phase I Clinical Development
- 9.5.2 Phase II Clinical Development
- 9.5.3 Phase III Clinical Development
9.6 Progress Analysis - Prostate Cancer
- 9.6.1 Phase I Clinical Development
- 9.6.2 Phase II Clinical Development
- 9.6.3 Phase III Clinical Development

10 Disclaimer

10.1 Liability
10.2 Completeness

11 Appendix I: Complete List of Apoptopic Drugs in Development in Oncology

12 Drug Index

13 Company Index

List of Boxes

Box 1: Business & Market - PXD-101
Box 2: Business & Market - MG-98
Box 3: Business & Market - VX-680
Box 4: Business & Market - Ceflatonin
Box 5: Business & Market - Oblimersen sodium
Box 6: Business & Market - motexafin gadolinium
Box 7: Business & Market - 1D09C3
Box 8: Business & Market - PCK-3145
Box 9: Business & Market - ME-2

List of Figures

Figure 1: Top 5 Countries in Apoptopic Cancer Research
Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug Development
Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
Figure 4: Distribution of ApoptopicTrials in Breast Cancer
Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer

List of Tables

Table 1: Top 10' s Apoptopic Pipeline Drugs
Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
Table 3: Companies with Apoptopic Cancer Drugs on the Market
Table 4: List of 120 Known Targets in Apoptosis Drug Development
Table 5: Known Targets of Late Stage Apoptopic Drugs Development
Table 6: Drugs with Bcl-2 as a Target
Table 7: Drugs with Casp-3 as a Target
Table 8: Drugs with CD4 molecule as a Target
Table 9: Drugs with Cova-1 as a Target
Table 10: Drugs with Eef-2 as a Target
Table 11: Drugs with Fnta as a Target
Table 12: Drugs with Fcer-2 as a Target
Table 13: Drugs with Hdac-1 as a Target
Table 14: Drugs with Hdac-2 as a Target
Table 15: Drugs with IL13-RA1 as a Target
Table 16: Drugs with Pde-2A as a Target
Table 17: Drugs with Pde-5A as a Target
Table 18: Drugs with Prkcb-1 as a Target
Table 19: Drugs with Srd-5A1 as a Target
Table 20: Drugs with Top-1 as a Target
Table 21: Drugs with Top-2A as a Target
Table 22: Drugs with Top-2A as a Target
Table 23: Drugs with p53 protein as a Target
Table 24: Breast Cancer Targets in Apoptopic Drug Development
Table 25: Leukemia Targets in Apoptopic Drug Development
Table 26: Lung Cancer Targets in Apoptopic Drug Development
Table 27: Lymhoma Targets in Apoptopic Drug Development
Table 28: Prostate Cancer Targets in Apoptopic Drug Development
Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic Drugs
Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for Breast Cancer
Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for Leukemia
Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for Lung Cancer
Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for Lymphoma
Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for Prostate Cancer